Andropause
QuatRx Pharmaceuticals Company initiates phase II trial of fispemifene for andropause
Published in Women's Health Weekly, March 23rd, 2006
Fispemifene is the company's product candidate for the treatment of the symptoms of andropause. This first randomized, double-blind, placebo-controlled, parallel group phase II study of fispemifene in the treatment of low testosterone in older men will seek to enroll approximately 100 patients at approximately 20 study sites in the United States. Patients will receive either 100, 200, or 300 mg fispemifene or placebo for 28 days.
The company also started dosing in a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Implants
Breast implants were not shown to increase long-term breast cancer risk - Cervical Cancer
Human papillomavirus tissue affinity may contribute to carcinogenic potential - Fibroids
Fibroids have low recurrence rates after laparoscopic uterine artery occlusion - HIV/AIDS Transmission
HIV-1 acquisition may be increased by vaginal washing practice in African women - Menopause
Soybean phytoestrogens may have very limited benefit on bone health - Angiology
Carotid artery intimal hyperplasia is improved by estrogen replacement in ovariectomized rats - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
